Citigroup’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-230,000
| Closed | -$1.04M | – | 5674 |
|
|
2026
Q1 | $1.04M | Sell |
230,000
-390,000
| -63% | -$1.71M | ﹤0.01% | 3095 |
|
|
2025
Q4 | $2.98M | Sell |
620,000
-225,000
| -27% | -$1.01M | ﹤0.01% | 2385 |
|
|
2025
Q3 | $3.84M | Buy |
845,000
+490,100
| +138% | +$1.8M | ﹤0.01% | 2172 |
|
|
2025
Q2 | $1.1M | Sell |
354,900
-5,000
| -1% | -$16.6K | ﹤0.01% | 3134 |
|
|
2025
Q1 | $1.26M | Buy |
359,900
+209,900
| +140% | +$700K | ﹤0.01% | 3088 |
|
|
2024
Q4 | $490K | Sell |
150,000
-167,400
| -53% | -$616K | ﹤0.01% | 3841 |
|
|
2024
Q3 | $1.22M | Buy |
317,400
+32,400
| +11% | +$124K | ﹤0.01% | 3102 |
|
|
2024
Q2 | $881K | Buy |
285,000
+50,000
| +21% | +$150K | ﹤0.01% | 2998 |
|
|
2024
Q1 | $606K | Sell |
235,000
-444,000
| -65% | -$1.15M | ﹤0.01% | 3436 |
|
|
2023
Q4 | $1.7M | Buy |
679,000
+484,600
| +249% | +$949K | ﹤0.01% | 2383 |
|
|
2023
Q3 | $395K | Sell |
194,400
-83,500
| -30% | -$175K | ﹤0.01% | 3234 |
|
|
2023
Q2 | $639K | Buy |
277,900
+94,400
| +51% | +$246K | ﹤0.01% | 3195 |
|
|
2023
Q1 | $556K | Buy |
+183,500
| New | +$518K | ﹤0.01% | 3048 |
|
|
2022
Q2 | – | Sell |
-24,200
| Closed | -$72K | – | 6184 |
|
|
2022
Q1 | $72K | Buy |
+24,200
| New | +$74.1K | ﹤0.01% | 4571 |
|
|
2020
Q4 | – | Sell |
-2,100
| Closed | -$7K | – | 7325 |
|
|
2020
Q3 | $7K | Buy |
2,100
+600
| +40% | +$1.82K | ﹤0.01% | 6808 |
|
|
2020
Q2 | $3K | Sell |
1,500
-11,700
| -89% | -$19.1K | ﹤0.01% | 7342 |
|
|
2020
Q1 | $13K | Buy |
13,200
+12,400
| +1,550% | +$33.5K | ﹤0.01% | 6916 |
|
|
2019
Q4 | $2K | Buy |
+800
| New | +$1.29K | ﹤0.01% | 7531 |
|
|
2019
Q2 | – | Sell |
-1,400
| Closed | -$5K | – | 7722 |
|
|
2019
Q1 | $5K | Sell |
1,400
-4,500
| -76% | -$17.3K | ﹤0.01% | 7404 |
|
|
2018
Q4 | $23K | Sell |
5,900
-5,300
| -47% | -$26.1K | ﹤0.01% | 6802 |
|
|
2018
Q3 | $106K | Buy |
11,200
+8,600
| +331% | +$85.4K | ﹤0.01% | 5836 |
|
|
2018
Q2 | $19K | Buy |
2,600
+1,600
| +160% | +$9.5K | ﹤0.01% | 6932 |
|
|
2018
Q1 | $5K | Buy |
+1,000
| New | +$5.3K | ﹤0.01% | 7190 |
|
|
2017
Q4 | – | Sell |
-4,200
| Closed | -$26K | – | 7535 |
|
|
2017
Q3 | $26K | Buy |
+4,200
| New | +$18K | ﹤0.01% | 6332 |
|
|
2017
Q2 | – | Sell |
-1,300
| Closed | -$4K | – | 7318 |
|
|
2017
Q1 | $4K | Sell |
1,300
-6,600
| -84% | -$18.3K | ﹤0.01% | 6841 |
|
|
2016
Q4 | $19K | Sell |
7,900
-4,900
| -38% | -$14.3K | ﹤0.01% | 6538 |
|
|
2016
Q3 | $44K | Sell |
12,800
-12,100
| -49% | -$47.3K | ﹤0.01% | 5737 |
|
|
2016
Q2 | $87K | Buy |
24,900
+10,900
| +78% | +$46.1K | ﹤0.01% | 5189 |
|
|
2016
Q1 | $58K | Sell |
14,000
-1,100
| -7% | -$3.93K | ﹤0.01% | 6026 |
|
|
2015
Q4 | $67K | Sell |
15,100
-1,000
| -6% | -$5.48K | ﹤0.01% | 5691 |
|
|
2015
Q3 | $98K | Sell |
16,100
-100
| -0.6% | -$887 | ﹤0.01% | 4997 |
|
|
2015
Q2 | $192K | Buy |
+16,200
| New | +$247K | ﹤0.01% | 4467 |
|
Other funds holding ABUS
Citigroup's ABUS Position: Q3 2026 in Review
Citigroup reduced its Arbutus Biopharma (ABUS) stake by 32% in Q3 2026, selling an estimated $1.38M and leaving 593,849 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2554.
Citigroup first reported a position in ABUS in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.22M in Q2 2026. 90 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.
- Citigroup held 593,849 shares of Arbutus Biopharma worth $2.84M as of Q3 2026.
- Citigroup sold 285,388 Arbutus Biopharma shares in Q3 2026, an estimated $1.38M.
- Arbutus Biopharma made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2554 holding.
- Citigroup first reported a position in Arbutus Biopharma in Q2 2013 and has held it in 53 quarters since.
- Citigroup's Arbutus Biopharma position peaked at $4.22M in Q2 2026.
- 90 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.